Premium
P4‐003: Designing a Randomized Placebo‐Controlled Crossover Trial Investigating Nabilone as a Treatment for Agitation in Patients with Moderate‐to‐Severe Alzheimer’s Disease
Author(s) -
Ruthirakuhan Myuri,
Herrmann Nathan,
Liu Celina,
Abraham Eleenor,
Kiss Alex,
Andreazza Ana C.,
Black Sandra E.,
Lanctot Krista L.
Publication year - 2016
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2016.06.2092
Subject(s) - placebo , randomized controlled trial , medicine , anesthesia , pathology , alternative medicine
P4-001 A LARGE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING RVT-101, A NEUROTRANSMITTER-TARGETED THERAPY, IN SUBJECTS WITH MILD-TOMODERATE ALZHEIMER’S DISEASE ON DONEPEZILTREATMENT: PHASE 3 MINDSET STUDY DESIGN Ilise Lombardo, Shari Coslett, David W. Liu, Kunal S. Kishnani, Benjamin Zimmer, Lawrence Friedhoff, Axovant Sciences, Inc., New York, NY, USA; 2 Roivant Sciences, Inc., New York, NY, USA. Contact e-mail: ilise.lombardo@axovant.com
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom